BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15200752)

  • 21. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.
    Wilkinson DG; Hock C; Farlow M; van Baelen B; Schwalen S
    Int J Clin Pract; 2002 Sep; 56(7):509-14. PubMed ID: 12296613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
    Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
    Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].
    Blesa R; García Ribas G; Galdós L; Olascoaga J; Amer G; Marey López J; Barquero M; Marsall C; Ezpeleta D
    Neurologia; 2006; 21(6):289-96. PubMed ID: 16799903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.
    Chankrachang S; Senanarong V; Poungvarin N; Phanthumchinda K; Tavichachart N; Praditsuwan R; Nidhinandana S
    J Med Assoc Thai; 2008 Sep; 91(9):1343-9. PubMed ID: 18843862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Risperidone in the treatment of psychotic, affective and behavioral symptoms associated to Alzheimer's disease].
    Barcia D; Giles E; Herraiz M; Moríñigo A; Roca M; Rodríguez A
    Actas Esp Psiquiatr; 1999; 27(3):185-90. PubMed ID: 10431061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
    Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease.
    Hart DJ; Craig D; Compton SA; Critchlow S; Kerrigan BM; McIlroy SP; Passmore AP
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1037-42. PubMed ID: 14618556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
    Schmidt R; Baumhackl U; Berek K; Brücke T; Kapeller P; Lechner A; Rainer M; Stögerer EM
    Neuropsychiatr; 2010; 24(2):125-31. PubMed ID: 20605008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.
    Mintzer JE; Kershaw P
    Int J Geriatr Psychiatry; 2003 Apr; 18(4):292-7. PubMed ID: 12673604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience of galantamine in dementia: a series of case reports.
    Dale MC; Libretto SE; Patterson C; Anderson J; Choudhury T; McCafferty F; McWilliam C; Richardson M
    Curr Med Res Opin; 2003; 19(6):508-18. PubMed ID: 14594523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
    Thavichachart N; Phanthumchinda K; Chankrachang S; Praditsuwan R; Nidhinandana S; Senanarong V; Poungvarin N
    Int J Clin Pract; 2006 May; 60(5):533-40. PubMed ID: 16700849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S; Wirth Y; Möbius HJ
    Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.